Monash University Discovery Uncovers Clue to Disarm Gonorrhea Superbug
Every year, more than 100 million people worldwide develop the sexually transmitted disease gonorrhea, with health consequences such as infertility, transmission of the disease to newborn babies, and increased risk of HIV infections. There has been a 63 percent rise in gonorrhea in Australia over the past five years.
Gonorrhoea is caused by bacteria which can rapidly develop resistance to all known antibiotics -- commonly called 'superbugs.' Gonorrhea superbugs have now been detected in every Australian state and territory and are increasingly difficult to treat in the clinic.
Monash University researchers have discovered a way the gonorrhoea bacteria cleverly evade the immune system - opening up the way for therapies that prevent this process, allowing the body's natural defences to kill the bug.
Published today in PLOS Pathogens, Dr. Thomas Naderer and Dr. Pankaj Deo and their team from the Monash Biomedicine Discovery Institute, have discovered how the gonorrhea-causing superbug (which is very small) creates even smaller packages of bacterial membrane blebs, termed vesicles, which attack immune cells.
Using cutting-edge super-resolution microscopy, which is able to see, and film, the most minute of events - the researchers found that these membrane vesicles interacted with the cells in the human immune system called 'macrophages', triggering these to die in an orchestrated suicide process. Macrophages are the cells within the immune system that ordinarily kill foreign invaders like bacteria and viruses, so without them the gonorrhoea bacteria can flourish.
Naderer said that this new understanding of how the gonorrhea bacteria interact and cause the death of immune system cells "may lead to strategies to combat gonorrhea infection and its symptoms".
The research may also provide information as to how other bacteria evade the immune system and be unaffected by antibiotics. The 2016 Review on Antimicrobial Resistance Final Report and Recommendations states that antibiotic resistant infection will kill an extra 10 million people a year worldwide - more than currently die from cancer - by 2050 unless action is taken.
Source: Monash Biomedicine Discovery Institute
Pioneering Advances in Sterilization: The Future of Infection Control
November 28th 2024Germitec, STERIS, ASP, and Zuno Medical are pioneering sterilization advancements with groundbreaking technologies that enhance SPD workflows, improve patient safety, and redefine infection control standards.
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
